Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Read more about Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Zafgen Reports Second Quarter 2015 Financial Results Read more about Zafgen Reports Second Quarter 2015 Financial Results Zafgen to Present at Canaccord Genuity 35th Annual Growth Conference 2015 Read more about Zafgen to Present at Canaccord Genuity 35th Annual Growth Conference 2015 Zafgen to Host Conference Call to Discuss Second Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss Second Quarter 2015 Financial Results Zafgen to Present at JMP Securities Life Sciences Conference 2015 Read more about Zafgen to Present at JMP Securities Life Sciences Conference 2015 Zafgen to Present at 2015 BIO International Convention Read more about Zafgen to Present at 2015 BIO International Convention Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome Read more about Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory Read more about Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory Zafgen Reports First Quarter 2015 Financial Results Read more about Zafgen Reports First Quarter 2015 Financial Results Zafgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome at ECO 2015 Read more about Zafgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome at ECO 2015 Pagination First page « First Previous page ‹ Previous … Page 14 Page 15 Page 16 Page 17 Current page 18 Page 19 Page 20 Page 21 Page 22 … Next page Next › Last page Last » Subscribe to
Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Read more about Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes
Zafgen Reports Second Quarter 2015 Financial Results Read more about Zafgen Reports Second Quarter 2015 Financial Results
Zafgen to Present at Canaccord Genuity 35th Annual Growth Conference 2015 Read more about Zafgen to Present at Canaccord Genuity 35th Annual Growth Conference 2015
Zafgen to Host Conference Call to Discuss Second Quarter 2015 Financial Results Read more about Zafgen to Host Conference Call to Discuss Second Quarter 2015 Financial Results
Zafgen to Present at JMP Securities Life Sciences Conference 2015 Read more about Zafgen to Present at JMP Securities Life Sciences Conference 2015
Zafgen to Present at 2015 BIO International Convention Read more about Zafgen to Present at 2015 BIO International Convention
Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome Read more about Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory Read more about Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Zafgen Reports First Quarter 2015 Financial Results Read more about Zafgen Reports First Quarter 2015 Financial Results
Zafgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome at ECO 2015 Read more about Zafgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome at ECO 2015